Table 1 Patient characteristics
From: Reduced pro-inflammatory profile of γδT cells in pregnant patients with rheumatoid arthritis
Healthy control | Rheumatoid arthritis | Ankylosing spondylitis | |
|---|---|---|---|
Total number | |||
Total | 35 | 55 | 31 |
Non-pregnant | 12 | 27 | 10 |
Pregnant | 23 | 28 | 21 |
Age in years; median (range) | |||
Non-pregnant | 30.5 (24–48) | 32.5 (17–51) | 35 (30–47) |
Pregnant | 33 (23–41) | 32 (28–39) | 32.5 (27–39) |
Rheumatoid factor positive | |||
Non-pregnant | 19 (59.4) | ||
Pregnant | 13 (46.4) | ||
ACPA positive | |||
Non-pregnant | 17 (53.1) | ||
Pregnant | 12 (42.9) | ||
HLA-B27 positive | |||
Non-pregnant | 7 (70) | ||
Pregnant | 14 (66.7) | ||
Medication | |||
NSAID | |||
Non-pregnant | – | 25 (75.8) | 7 (70) |
3rd trimester | – | 4 (14.3) | 5 (23.8) |
Postpartum* | – | 7 (25) | 9 (42.9) |
Prednisone** | |||
Non-pregnant | – | 12 (36.4) | 1 (10) |
3rd trimester | – | 13 (46.4) | 3 (14.3) |
Postpartum* | – | 9 (32.1) | 2 (9.5) |
Sulfasalazine | |||
Non-pregnant | – | 8 (24.2) | 1 (10) |
3rd trimester | – | 5 (17.9) | – |
Postpartum* | – | 7 (25) | 1 (4.8) |
Antimalarials | |||
Non-pregnant | – | 1 (3) | – |
3rd trimester | – | 2 (7.1) | – |
Postpartum* | – | 5 (17.9) | – |
Methotrexate | |||
Non-pregnant | – | 7 (21.2) | – |
3rd trimester | – | – | – |
Postpartum* | – | – | – |
Leflunomide | |||
Non-pregnant | – | 1 (3) | – |
3rd trimester | – | – | – |
Postpartum* | – | – | – |
TNF inhibitors | |||
Non-pregnant | – | 5 (15.2) | 3 (30) |
3rd trimester | – | – | – |
Postpartum* | – | 2 (9.5) | |